Naphthyl Derivatives as Inhibitors of Beta-Amyloid Aggregation
申请人:Minetti Patrizia
公开号:US20080255232A1
公开(公告)日:2008-10-16
Compounds useful in the treatment of disorders characterized by deposits of amyloid aggregates are herein described together with pharmaceutical compounds containing the same. In particular the compounds of the present invention are those having the Formula (I) as reported below, where the radicals have the meaning indicated in the description.
Dyes like CR are able to inhibit the aggregation of A beta fibrils. Thus, a screening of a series of dyes including ABBB (1) was performed. Its main component 2 tested in an in vitro assay (i.e., ThT assay) showed good potency at inhibiting fibrils association. Congeners 4-9 have been designed and synthesized as inhibitors of A beta aggregation. A nurnber of these newly synthesized compounds have been found to be active in the ThT assay with IC50 of 1-57.4 mu M. The most potent compound of this series, 4k, showed micromolar activity in this test. Another potent derivative 4q (IC50 = 5.6 mu M) rapidly crossed the blood-brain barrier, achieving whole brain concentrations higher than in plasma. So 4q could be developed to find novel potent antiaggregating beta A agents useful in Alzheimer disease as well as other neurological diseases characterized by deposits of amyloid aggregates.
NAPHTHYL DERIVATIVES AS INHIBITORS OF BETA-AMYLOID AGGREGATION
[EN] NAPHTHYL DERIVATIVES INHIBITORS OF THE BETA-AMYLOID AGGREGATION<br/>[FR] DERIVES DE NAPHTYLE INHIBITEURS DE L'AGREGATION DE BETA-AMYLOIDE
申请人:SIGMA TAU IND FARMACEUTI
公开号:WO2007045593A2
公开(公告)日:2007-04-26
[EN] Compounds useful in the treatment of disorders characterised by deposits of amyloid aggregates are herein described together with pharmaceutical compounds containing the same. In particular the compounds of the present invention are those having the Formula (I) as reported below. where the radicals have the meaning indicated in the description. [FR] L'invention concerne des composés que l'on utilise dans le traitement de troubles se caractérisant par des dépôts d'agrégats d'amyloïdes, ainsi que de composés pharmaceutiques les contenant. Plus précisément, les composés selon l'invention sont ceux de la formule ci-dessous, où les radicaux ont la signification indiquée dans le descriptif.